Microphysiological models for the assessment of pulmonary concentration of inhaled aerosols

雾化吸入是肺部疾病的首选治疗方法。尽管它们通常用于治疗，但关于它们在肺内的药代动力学曲线存在许多不确定性，这与现场测量特性的困难有关。了解沉积区域和局部渗透率将有助于阐明吸入化合物的吸收过程。鉴于此，需要一种新的模式。为了减少成本和动物负担，体外试验是一个直接的解决方案。一种名为芯片上器官的新兴技术开辟了生物相关调查工具的新前沿，可以在微尺度上对器官进行3D平移。这项建议的核心是就肺药代动力学方面的知识差距的现状进行综述，并为构建体外模型提供要素，以解决这些问题。

Inhaled aerosols are the treatment of choice for pulmonary diseases. Despite their common therapeutic use, many uncertainties regarding their pulmonary pharmacokinetic profile exist, linked to the difficulty of measuring properties in place. Knowing the region of deposition and local rate of permeation would allow elucidation of absorption processes for inhaled compounds. Given that, a new model is required. To cut costs and animal burden, in vitro assay is a straightforward solution. An emerging technology known as organ-on-chip has opened a new frontier of biorelevant investigative tools, allowing a 3D translation of organs on a microscale. The core of this proposal is to present a review of the current state-of-the-art in terms of knowledge gaps in pulmonary pharmacokinetics and provide elements for the construction of an in vitro model, to address such questions.